An ideal nondiabetogenic, nonnephrotoxic immunosuppressive protocols for pancreas transplantation

Current Opinion in Organ Transplantation

Volumn 8, Issue 2, 2003, Pages 186-189

  Gaber, Lillian W ^a   Egidi, M Francesca ^a   Gaber, A Osama ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846941339     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/00075200-200306000-00010     Document Type: Review

References (28)

1. Gruessner A, Sutherland DE: Pancreas transplantation in the United States (US) and non-US as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin Transplant 1996, 47.
2. Gruessner AC, Sutherland DE: Analysis of United States (US) and non-US pancreas transplants reported to the United network for organ sharing (UNOS) and the international pancreas transplant registry (IPTR) as of October 2001. Clin Transplant 2001, 41.
3. Stratta RJ, Alloway RR, Hodge E, et al.: A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 2002, 16:60.
4. Philosophe B, Farney AC, Schweitzer EJ, et al.: Superiority of portal venous drainage over systemic venous drainage in pancreas transplantation: a retrospective study. Ann Surg 2001, 234:689.
5. Stegall MD, Kim DY, Prieto M, et al.: Thymoglobulin induction decreases rejection in solitary pancreas transplantation. Transplantation 2001, 72:1671.
6. Sinclair NR: Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicenter Transplant Study Group. Can Med Assoc J 1992;147:645.
7. Schulak JA, Mayes JT, Moritz CE, et al.: A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporinetreated and azathioprine-treated renal transplant patients. Transplantation 1990, 49:327.
8. Ahsan N, Hricik D, Matas A, et al.: Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999, 68:1865.
9. Cantarovich D, Giral-Classe M, Hourmant M, et al.: Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000, 69:1505.
10. Gruessner RW, Sutherland DE, Parr E, et al.: A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant Proc 2001, 33:1663.
11. Kaufman DB, Leventhal JR, Koffron AJ, et al.: A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002, 73:169.
12. Almawi WY, Lipman ML, Stevens AC, et al.: Abrogation of glucocorticoidmediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991, 146:3523.
13. Almawi WY, Hess DA, Assi JW, et al.: Pretreatment with glucocorticoids enhances T-cell effector function: possible implication for immune rebound accompanying glucocorticoid withdrawal. Cell Transplant 1999, 8:637.
14. MacDonald A: Improving tolerability of immunosuppressive regimens. Transplantation 2001, 72 (suppl):S105.
15. Barone GW, Ketel BL, Abul-Ezz SR, et al.: Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation. J Pancreas 2002, 3:49.
16. Houde I, Isenring P, Boucher D, et al.: Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation? Transplantation 2000, 70:1251.
17. Keunecke C, Rothenpieler U, Zanker B, et al.: Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc 2000, 32(suppl):6S.
18. Theodorakis J, Schneeberger H, Illner WD, et al.: Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors. Transplant Proc 2000, 32(suppl):9S.
19. Vincenti F, Ramos E, Brattstrom C, et al.: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001, 71:1282.
20. Kahan BD, Kaplan B, Lorber MI, et al.: RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001, 71:1400.
21. MacDonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271.
22. Flechner SM, Goldfarb D, Modlin C, et al.: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002, 74:1070.
23. Kreis H: New strategies to reduce nephrotoxicity. Transplantation 2001, 72 (suppl):S99.
24. Lo A, Egidi MF, Gaber LW, et al.: Comparison of two different rapamycinbased immunosuppressive regimen in cadaveric renal transplantation [abstract]. American Transplant Congress, 2003.
25. Vasquez A, for the RAD SKP Study Group. Safety and tolerability of everolimus in simultaneous pancreas-kidney transplantation (spk) in combination with Simulect, Neoral and corticosteroids [poster]. American Transplant Congress, 2003.
26. Langer RM, Kahan BD: Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002, 74:804.
27. Hardinger KL, Wang CD, Schnitzler MA, et al.: Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2002, 2:867.
28. Budde K, Schmouder RL, Brunkhorst R, et al.: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002, 13:1073.